18 June 2025 – Minneapolis, MN – Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that the Vision-MR Ablation Catheter 2.0 and Vision-MR Diagnostic Catheter are commercially available for clinical use across Europe.
Designed for use in interventional cardiac MRI (iCMR) environments, the Vision-MR Ablation Catheter 2.0 features a range of physician-driven enhancements, including two curve sizes and enhanced deflection control, while preserving the same trusted MR-compatible design physicians trust. These new design elements reflect just a few of the purposeful improvements incorporated to elevate the performance and usability of Vision-MR Ablation Catheter 2.0.
In parallel, the Vision-MR Diagnostic Catheter provides real-time electrophysiological mapping during active MRI scanning while leveraging the superior visualization of cardiac anatomy that the MRI provides.
Both the Vision-MR Ablation Catheter 2.0 and the Vision-MR Diagnostic Catheter are being used in Imricor’s VISABL-AFL and VISABL-VT clinical trials that are currently enrolling.
As the only company offering a full solution for performing real-time cardiac ablations inside the MRI, Imricor continues to lead the transformation of electrophysiology by enabling ablation therapy guided by the superior imaging capabilities of MRI.
Imricor’s Chair and CEO, Steve Wedan, commented: “These two new catheter families, both CE marked under the European Union’s Medical Device Regulations (EU MDR), mark the next evolution of MRI-guided cardiac ablation and the launching of Imricor’s platform for the future.”
